Kris V. Kowdley MD, FACP, FACG, AGAF, FAASLD is Director of the Liver Care Network, and Organ Care Research at Swedish Medical Center located in Seattle, Washington. Dr. Kowdley received his BS in Biology and Anthropology as a member of the Dean's List at Columbia University, and his medical degree from Mount Sinai School of Medicine. He completed his internship and residency at Oregon Health Science University and a Fellowship in Gastroenterology and Hepatology at Tufts University School of Medicine. Dr. Kowdley is recognized as a world-renowned leader in the field of hepatology, and has presented his research on liver diseases at more than 135 national and international meetings and scientific symposia. He is the author of over 375 articles, book chapters, reviews and commentaries in professional publications. Dr. Kowdley also maintains an active practice in hepatology and has interests and expertise in specialized genetic liver diseases, fatty liver disease, viral hepatitis, and cholestatic liver diseases.Read More
Kowdley KV, Lawitz E, Crespo I, Hassanein T, Davis MN, Demicco M, Bernstein DE, Afdhal N, Vierling JM, Gordon SC, Anderson JK, Hyland RH, Dvory-Sobol H, An D, Hindes RG, Albanis E, Symonds WT, Berrey MM, Nelson DR, Jacobson IM. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naïve patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet. 2013 Jun 15;381(9883):2100-7.
Kanwar P, Kowdley KV. Metal storage disorders: Wilson disease and hemochromatosis. Med Clin North Am. 2014 Jan;98(1):87-102.
Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson DR, Zeuzem S, Everson GT, Kwo P, Foster GR, Sulkowski MS, Xie W, Pilot-Matias T, Liossis G, Larsen L, Khatri A, Podsadecki T, Bernstein B. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med. 2014 Jan 16;370(3):222-32.
Kowdley KV. Advances in the diagnosis and treatment of nonalcoholic steatohepatitis. Gastroenterol Hepatol (N Y). 2014 Mar;10(3):184-6.
Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, Shiffman ML, Schiff E, Ghalib R, Ryan M, Rustgi V, Chojkier M, Herring R, Di Bisceglie AM, Pockros PJ, Subramanian GM, An D, Svarovskaia E, Hyland RH, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Pound D, Fried MW; the ION-3 Investigators. Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis. N Engl J Med. 2014 May 15;370(20):1879-88.
Minaei AA, Kowdley KV. ABT-450/ ritonavir and ABT-267 in combination with ABT-333 for the treatment of hepatitis C virus. Expert Opin Pharmacother. 2015 Apr;16(6):929-3.
Lindor KD, Kowdley KV, Harrison ME. ACG Clinical Guideline: Primary Sclerosing Cholangitis. Am J Gastroenterol. 2015 May;110(5):646-59.
Kowdley KV, An D, Pang PS, Wyles D. Analysis of subgroup differences in the ION-3 trial of ledipasvir-sofosbuvir in chronic hepatitis C infection. Open Forum Infectious Diseases. 2015 2(2):ofv056.
Ness E, Kowdley KV. Update on Hepatitis C: epidemiology, treatment and resistance to antiviral therapies. Minerva Gastroenterol Dietol. 2015 Sep;61(3):145-58.
The Patient Rating score is based on responses given during the CAHPS Patient Experience Survey. Comments are also gathered from the same survey and displayed in their entirety with the exception of any language that may be considered slander, libel or contain private health information, which will be removed prior to publishing the comments. Responses are measured on a 10 - point scale, with 10 being the best score. These scores are then translated to a 5 - point scale in order to display results in a 5 - star rating. More About Our SurveyRead More